Dr. Chang studies the pathogenesis of esophageal cancer with a particular interest in the mechanisms of esophageal adenocarcinoma treatment resistance and chemoprevention. His collaboration through the Michigan Medicine-Peking University Health and Science Center Joint Institute utilizes high-throughput sequencing and tetramer flow cytometry to identify tumor-specific neoantigens derived from patients with non-small cell lung carcinoma, both adenocarcinomas and squamous cell carcinomas, as a prelude to the treatment of NSCLC patients with autologous T cells.
Andrew Chang, MD
John Alexander Distinguished Professor of Thoracic Surgery
Professor of Surgery
Section Head, Thoracic Surgery
Countries of Interest: China